COVID-19 Resources for Clinicians
(Updated September 14, 2020)
The United States and countries around the world face a major public health concern with the current outbreak of the novel (new) coronavirus (COVID-19). In an effort to serve its members, ASH is maintaining this webpage as a medium to exchange information to assist hematologists in navigating the COVID-19 public health crisis.
While ASH aims to provide a forum for the exchange of information that is helpful, accurate and up-to-date, the relevant health information and data concerning the disease, as well as the various governmental actions and responses to the disease, are changing constantly, and ASH makes no representation, warranty, or guaranty whatsoever as to any information that may be exchanged through this webpage.
-
Treatments and Prevention
- COVID-19 and Convalescent Plasma (Version 5.0; last updated August 25, 2020)
-
Malignant Topics
- COVID-19 and Aggressive Non-Hodgkin Lymphoma (Version 3.1; last updated August 4, 2020)
- COVID-19 and Acute Lymphoblastic Leukemia - Adult (Version 1.2; last reviewed September 14, 2020)
- COVID-19 and Acute Lymphoblastic Leukemia - Pediatric (Version 2.0; last reviewed July 27, 2020)
- COVID-19 and Acute Myeloid Leukemia (Version 1.2; last updated September 13, 2020)
- COVID-19 and Chronic Lymphocytic Leukemia (Version 3.0; last updated August 5, 2020)
- COVID-19 and Chronic Myeloid Leukemia (Version 1.2; last updated July 20, 2020)
- COVID-19 and Hodgkin Lymphoma (Version 3.1; last updated August 4, 2020)
- COVID-19 and Indolent Lymphomas (Version 3.1; last updated August 4, 2020)
- COVID-19 and Myelodysplastic Syndromes (Version 3.1; last updated September 14, 2020)
- COVID-19 and Myeloproliferative Neoplasms (Version 3.0; last updated July 20, 2020)
- COVID-19 and Multiple Myeloma (Version 1.2; last reviewed September 14, 2020)
- COVID-19 and HCT (Version 1.0; last updated July 20, 2020)
-
Non-Malignant Topics
- COVID-19 and Aplastic Anemia (Version 1.1; last reviewed July 20, 2020)
- COVID-19 and Coagulopathy (Version 3.0; last reviewed July 20, 2020)
- COVID-19 and Immune Thrombocytopenic Purpura (Version 4.0; last updated July 23, 2020)
- COVID-19 and Pulmonary Embolism (Version 2.0; last reviewed July 20, 2020)
- COVID-19 and Sickle Cell Disease (Version 4.0; last updated June 18, 2020)
- COVID-19 and Thalassemia (Version 2.0; last updated June 8, 2020)
- COVID-19 and Thrombotic Thrombocytopenic Purpura (Version 2.0; last updated July 22, 2020)
- COVID-19 and VTE/Anticoagulation (Version 4.0; last updated July 20, 2020)
-
Clinical Laboratory Topics
- COVID-19 and aPL Antibodies (Version 1.0; last updated April 20, 2020)
- COVID-19 and D-dimer (Version 1.0; last updated April 20, 2020)
- COVID-19 and Viscoelastic Hemostasis Assays (Version 1.0; last updated May 11, 2020)
-
Clinical FAQ Resources from Other Societies
COVID-19 Treatments
Guidance About COVID-19 Treatment
- SCD Patients Presenting to the Emergency Department During the COVID-19 Pandemic: Considerations and a Checklist
- Assessment of Evidence for COVID-19 related treatments
- Tables of COVID-19 drug-drug interactions
- NIH COVID treatment guidance
- COVID Ready Communication Skills: A playbook of VitalTalk Tips
- CDC Clinician On-Call Center
24-hour access to CDC clinicians to answer COVID-19 questions. - ASH Webinar on COVID-19 and Thrombosis
Clinical Trials and Studies
- COVID Clinical Trials Explorer
- COVID-19 Clinical Trial Tracker
- ClinicalTrials.gov
- Convalescent plasma clinical trials
COVID-19 Registries for Hematologic Conditions
- ASH RC COVID-19 Registry for Hematology
The ASH Research Collaborative’s (ASH RC) Data Hub is capturing data on people who test positive for COVID-19 and have been or are currently being treated for a hematologic condition. As data are received, near real-time observational data summaries are reported for clinicians on the front line of the COVID-19 pandemic. Clinicians and other health care providers worldwide are invited to enter de-identified data on all confirmed COVID-19 cases for hematology patients, regardless of recovery or active treatment status. Online data entry takes approximately 5 minutes to complete. - Secure-SCD Registry (Medical College of Wisconsin)
This registry is designed to capture pediatric and adult COVID-19 cases that are occurring across the world in patients living with sickle cell disease. - CCC19 (COVID-19 and Cancer Consortium)
A consortium of over 100 cancer centers and other organizations who have come together to collect data about cancer patients who have been infected with COVID-19.
Restarting Routine Clinical Practice
- AMA Physician Practice Guide to Reopening
- CMS Guidance on re-opening facilities to non-COVID care
- ASCO guide to cancer care delivery during COVID
Academic Centers, Hospitals, and Community Practices
- Brigham and Women's Hospital (COVID-19 Critical Care Clinical Guidelines)
- COA (Community Oncology Alliance) (Administrator and Clinician Tools, Patient-facing materials)
- Seattle Cancer Care Alliance (patient screening and testing tools, PPE donning and doffing videos, telehealth FAQs)
- University of Washington (Screening and testing algorithms, policies and procedures)
Additional Resources
American Society of Hematology
- ASH Policy Resources
- ASH Summary of the Coronavirus Aid, Relief and Economic Security (CARES) Act
- Latest COVID-19 Resources from ASH Publications
- Blood: Latest COVID-19 Articles
- Blood Advances: Latest COVID-19 Articles
- ASH Clinical News: COVID-19 News
- The Hematologist: COVID-19 Articles and Podcasts